About Us

About the Lab

WHO WE ARE

The Princess Margaret Cancer Centre-Ontario Institute for Cancer Research Translational Genomics Lab (PM-OICR TGL) is a joint collaborative workspace located in the MaRS complex at University Avenue and College Street in downtown Toronto.

WHAT WE DO

TGL, a department of OICR Genomics, facilitates genomic interpretation and annotation for rapid accredited reporting for clinical oncology studies.

TGL provides research support to the Princess Margaret Cancer Centre and affiliated cancer research institutions as part of OICR’s Adaptive Oncology Program. TGL is formulated to accelerate clinical oncology research through partnerships that drive innovation in clinical genomics.

OUR KEY INITIATIVES

  • Facilitate access to genome-wide multi-omic assays from pathology specimens including Formalin Fixed Paraffin Embedded (FFPE), fresh frozen and Laser Capture Macrodissected (LCM) tumor tissues, and plasma

  • Clinically report whole genome, whole transcriptome and circulating tumor DNA based assays with rich clinical annotation for actionable genomic variants, including structural rearrangements, indels, copy number changes, single nucleotide variants, fusions and expression outliers

  • Share and continuously improve integrated analysis methods Github to facilitate robust tumor phenotypic classification

  • Facilitate actionable mutation detection through an emphasis on multiplatform molecular diagnostics, including IQMH/CAP accredited transcriptome, whole genome and targeted circulating tumor DNA based assays

  • Facilitate rapid genomic annotation and integration of tumor H&E imaging through cBioPortal and streamlined requisition submission through web-accessible portals

About the Research

TGL participates in clinical trial research through the Princess Margaret Cancer Genomics (CGP) and Tumor Immunotherapy Programs (TIP), providing extended capabilities and infrastructure.

PROJECT OCTANE

TGL is supporting the Ontario-wide Targeted Nucleic Acid Evaluation (OCTANE) Trial, which is increasing cancer patient access to next-generation sequencing (NGS) technology and rapid informatic analysis in therapeutic management.

OCTANE is establishing large provincial cohorts of consented patients for NGS-based genomic profiling that may inform the use of approved therapies and identify patients that may benefit from advanced molecular profiling within TGL.

CLINICAL LABORATORY WORK

TGL prioritizes clinical laboratory and computational capabilities to validate novel oncology assays witih rich clinical annotation. We follow best practices through our Quality Management System based on the principles of ISO15189. We are entering our pre-accreditation phase for certification by the following licensing bodies:

  • College of American Pathologist (CAP)
  • Clinical Laboratory Improvement Amendments (CLIA)
  • Institute for Quality Management in Healthcare (IQMH)

Research Studies

TGL participates in a variety of clinical research studies including:

  • Genomic Investigation of Unusual Responders (GENIUS)
  • Integrative Sequencing in Germline and Hereditary Tumors (INSIGHT)
  • Comprehensive Translational Research Study of Head and Neck Tumors
  • Determinants of Outcome in Medulloblastoma and Ependymoma in Ontario
  • Accelerated Identification and Validation of Novel Molecular Signatures to Improve Treatment in Early Stage Non-small Cell Lung Cancer Patients
  • Retrospective Analysis of Clonal Evolution and Tumor Heterogeneity from IMPACT (REACT)
  • Investigator Initiated Phase II Study of Pembrolizumab Immunological Response Evaluation (INSPIRE)
  • Biallelic Mismatch Repair Deficiency Syndrome (bMMRD)
  • Novel Universal Classification of Childhood Low Grade Gliomas using Clinicopathological and Molecular Methods
  • Comprehensive Genomic Characterization of Lung Adenocarcinoma in Never Smokers
  • Treatment-free Remission Accomplished with Dasatinib in Patients with CML
  • Molecular Testing of Tumor Samples as a Classification Tool
  • An Open-label, Phase Basket Study of Hypomethylating Agent Oral Azacitidine and Durvalumab in Advanced Solid Tumors (METADUR)
  • plus many more!

Contact Us

Dr. Dax Torti

Project Manager

PM-OICR Translational Genomics Lab

647-260-7938, dax.torti@oicr.on.ca

Ontario Institute for Cancer Research (OICR)

MaRS Centre
661 University Avenue
Toronto, Ontario M5G 0A3
Canada